Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies
2016-000461-23Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in Non-hematologic malignancy and cancer, sponsored by Bristol Myers Squibb. Primary endpoint: Objective Response Rate (ORR). Started Sep 2016; status: completed.
02
Drugs
03
Conditions
Non-hematologic malignancycancer
Beyond the preview
Go deeper on 2016-000461-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000461-23.